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Abstract
Background: Gene transduction has been considered advantageous for the sustained delivery of proteins to specific target
tissues. However, in the case of hard tissues, such as bone, local gene delivery remains problematic owing to anatomical
accessibility limitations of the target sites.
Methodology/Principal Findings: Here, we evaluated the feasibility of exogenous gene transduction in the interior of bone
via axonal transport following intramuscular administration of a nonviral vector. A high expression level of the transduced
gene was achieved in the tibia ipsilateral to the injected tibialis anterior muscle, as well as in the ipsilateral sciatic nerve and
dorsal root ganglia. In sciatic transection rats, the gene expression level was significantly lowered in bone.
Conclusions/Significance: These results suggest that axonal transport is critical for gene transduction. Our study may
provide a basis for developing therapeutic methods for efficient gene delivery into hard tissues.
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Introduction
Defective bone healing is a major clinical problem. The ability to
promote osteogenesis ina controlled waywould be beneficial for the
treatment of bone fractures and large segmental bone defects, for
the fixation of artificial joints and for avoiding nonunion or delayed
union of fractures [1]. When therapeutic genes, such as bone
morphogenetic protein (BMP) cDNAs, are supplied to bone
fractures and bone defects, they can offer sustained delivery of
proteins to a local area. Thus, local gene delivery into bone has a
huge therapeutic potential for the treatment of bone diseases. Ex vivo
and in vivo therapeutic procedures for gene delivery to local bone
tissuehavebeenreported{reviewedin[2]}:i)thegeneisintroduced
into cultured cells, which are then implanted into the patient (ex vivo
transfer) [3–6], or ii) the gene is transferred directly into the target
sites (in vivo transfer) [7–11]. Ex vivo methods are safer in terms of the
fact that the toxic or immunogenic effects of reagents are
minimized; however, they pose risks of potential bacterial and/or
infectious contamination caused by manipulating cells ex vivo,a n do f
mix-ups of samples and the phenotypic transformation of the cells.
On the other hand, in vivo gene therapy is technically simple and less
invasive[12].Inthecaseofcalcified tissues,however,thein vivo local
delivery of an exogenous gene remains problematic because of the
limited accessibility into the bone tissue [13]. To avoid the possible
defects caused by ex vivo and in vivo gene transfer, systemic gene
transfer via the vascular system has been tested for the reversal of
osteopenia in ovariectomized mice [14,15]. However, systemic gene
delivery has been reported to cause severe side effects including
strong immune responses to reagents related to the gene delivery
[9,16,17].
Anatomically, sensoryand sympathetic nerve fibers arepresent in
bone, and they form dense parallel networks around blood vessels
contiguous to bone trabeculae in close contact with bone cells [18],
andplayanimportantrole inbone metabolism[19–22].Thus,close
anatomical and functional relationships have been found between
bone and the nervous system. Previously, we demonstrated that a
nonviral vector could transfer a gene successfully into peripheral
nerves, dorsal root ganglia, and the spinal cord via retrograde
axonal transport from an injected muscle [23]. In this study, to test
the hypothesis that genes transfer to bone tissue via complicated
networks between bone and the nervous system, we evaluated the
efficacy of gene expression in the interior of bone via axonal
transport following intramuscular injection of a nonviral vector
[HVJ (hemagglutinating virus of Japan) envelope].
Materials and Methods
Ethics Statements
This experimental study was carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
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protocol was approved by the Committee on the Ethics of Animal
Experiments of the National Defense Medical College.
Construction of luciferase plasmid DNA
To evaluate transfection efficiency, we used a pcDNA/GL3
luciferase plasmid vector, which was a kind gift from Dr.
Yasuhumi Kaneda (Osaka University, Japan). The pcDNA/GL3
luciferase plasmid vector (7.4 kb) was constructed by cloning the
luciferase gene from the pGL3-Promoter Vector (Promega, WI,
USA) into pcDNA3 (5.4 kb) (Invitrogen, CA, USA) at the Hind III
and BamH I sites. The pGL3 promoter vector containing the SV40
promoter was inserted into the pcDNA3 vector containing a
cytomegalovirus promoter (5.4 kbp) between the Hind III and
BamH I sites.
Preparation of an HVJ envelope/luciferase gene complex
vector
The HVJ envelope/luciferase gene complex vector was
prepared using an HVJ envelope vector kit (GenomOne-Neo;
Ishihara Sangyo, Osaka, Japan). Briefly, freeze-dried HVJ
envelopes (100 ml) were reconstituted and placed into a micro-
test tube. An incorporation reagent (10 ml) was added to the HVJ
envelope suspension and agitated. The mixture was centrifuged
(12000 rpm, 4uC, 10 min), and the supernatant was discarded.
The sediment was suspended in the buffer (25 ml) supplied with the
kit and mixed with luciferase plasmid DNA/TE solution (25 ml), to
yield a vector concentration of 4 mg/ml. After being left to stand
for 5 min, the HVJ envelope/luciferase gene complex vector
(1 mg/ml) was used immediately.
Injection of an HVJ envelope/luciferase gene complex
vector into the tibialis anterior
Eighty-eight male Wistar rats, approximately 7 weeks old and
weighing 150–170 g, were used in this study. Seventy-two rats
were used for the evaluation of gene expression [luciferase activity
and reverse transcription polymerase chain reaction (RT-PCR)],
nine were used to assess gene distribution, and the remaining
seven were subjected to sciatic nerve transection. They were
housed in a temperature-controlled room with a 12-hour light-
dark cycle.
All surgical procedures were carried out under sodium
pentobarbital anesthesia (30–50 mg/kg body weight, intraperito-
neally injected). HVJ envelopes (100 ml) containing 100 mgo f
luciferase reporter plasmid were carefully injected percutaneously
into the proximal one-third of the tibialis anterior muscle of the
right hindlimb via a 27-gauge needle (Terumo, Atsugi, Japan),
each injection taking 3 to 5 min so as to avoid leakage out of the
fascia.
Analysis of luciferase activity
Luciferase activity was measured using a luciferase assay system
(Promega, WI, USA). Forty-two rats were used to evaluate the
transfection efficiency of an HVJ-envelope complex vector. The
injected muscle (tibialis anterior), bilateral sciatic nerves, bilateral
dorsal root ganglia (L4, L5), bilateral femora, bilateral tibiae, and
bone marrows from bilateral femora and tibiae were harvested as
specimens on days 1, 3, 5, 7, 10, and 12 after the transfer of a
pcDNA/GL3 luciferase plasmid (n=7 for each day after
transfection) (Fig. 1A). In addition, fourteen rats were used to
evaluate the transfection efficiency of an HVJ-envelope complex
vector following a second gene transfer (performed on day 7 after
the first gene transfer, using the same injection procedure into the
same place in the muscle as the first). This time, specimens were
harvested on days 3 and 5 after the second gene transfer (n=7 for
each day after the second transfection) (Fig. 1A). Twelve rats were
used as controls. Samples were harvested on days 1 and 3 after the
injection of phosphate buffered saline (PBS) (100 ml) (n=6 for each
day after injection). Bone marrows were flushed out, and periostea
were thoroughly stripped from bones before sampling to avoid
contamination with muscles (Fig. 1A). Then, the samples were
rapidly frozen in liquid nitrogen and homogenized in a cell-culture
lysis reagent [in advance, mineral bones were crushed using a
Cryo-Press (Microtec, Chiba, Japan)]. Subsequently, the tissue
lysates were briefly centrifuged (12000 rpm, 4uC, 3 min), and
20 ml of supernatant was mixed with 100 ml of luciferase assay
reagent. The luminescence reaction was quantified using a Lumat
LB 9507 (Berthold Technologies, Bad Wildbad, Germany), and
the residual supernatant was used in a colorimetric assay of protein
concentration, for which a DC protein assay system (Bio-Rad
Laboratories, CA, USA) and a Model 680 Microplate Reader
(Bio-Rad Laboratories, CA, USA) were used. The luminescence
reaction, as adjusted by the concentration of protein, was used as
an index of luciferase activity.
Immunohistochemistry for luciferase and calcitonin
gene-related peptide (CGRP)
Nine rats were used for immunohistochemical staining.
Tibialis anterior muscles, sciatic nerves, dorsal root ganglia,
and tibiae were harvested on day 3 after the first gene transfer.
The specimens (except for bones) were then rapidly embedded in
an optimal cutting temperature (OCT) compound and frozen at
280uC. Sagittal sections of 6 mm thickness were cut serially on a
cryostat and mounted on silane-coated slides. Specimens of bones
were embedded in carboxymethyl cellulose (CMC) compound
and frozen at 280uC. Tibial cross sections of 10 mm thickness
[cut using a tungsten carbide blade after trimmed surfaces had
been covered with Cryofilm (Finetec, Tokyo, Japan)] were
mounted on slides. After being air-dried for 30 min, the sections
were immersed and fixed in 0.1 M phosphate buffer (pH 7.4)
containing 4% paraformaldehyde, and rinsed in running water.
Then, they were treated with 2% bovine serum albumin in PBS
for 10 min at room temperature to block nonspecific protein
binding, and incubated overnight at 4uCi nah u m i d i f i e d
chamber with a polyclonal antibody against recombinant firefly
luciferase (Promega, WI, USA) diluted at 1:100. The sections
were rinsed in PBS and incubatedw i t ha na n t i - g o a tI g GF I T C -
conjugated secondary antibody (Chemicon, CA, USA) diluted at
1:50 for 2 h. After further rinsing in PBS, the sections were finally
immersed in 49, 6-diamidino-2-phenylindole (DAPI) for 15 min
to stain nuclei.
To identify the location of intra-osseous sensory nerve fibers,
tibial serial sections were stained with an anti-calcitonin gene-
related peptide (CGRP) antibody (Biomol, PA, USA). The sections
were air-dried for 10 min at room temperature and fixed in 0.1 M
phosphate buffer (pH 7.4) containing 4% paraformaldehyde, and
rinsed in running water. Then, they were treated with 3% H2O2 in
90% methanol for 5 min to inactivate endogenous peroxidase.
They were rinsed with PBS for 30 min and treated with 2%
bovine serum albumin in PBS for 10 min at room temperature to
block nonspecific protein binding. Then, they were stained with a
rabbit anti-CGRP polyclonal antibody (Biomol, PA, USA) diluted
at 1:500 for 3 days at 4uC in a humidified chamber. The sections
were rinsed in PBS and incubated for 24 h in a Histofine simple
stain MAX-PO (rabbit) secondary antibody (Nichirei, Tokyo,
Japan) at 4 uC in a humidified chamber. After further rinsing in
PBS, they were immersed in peroxidase with 3,3-diaminobenzi-
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PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e13034Figure 1. Geneexpression in the interiorof the bone by intramuscular administrationof an HVJ-envelope-DNA complex.(A) Experimental
designofgenetransfer.Aluciferase/HVJ-Evector(100 ml) containing100 mg luciferaseplasmid DNAwascarefully injected percutaneouslyinto theproximal
one-third ofthetibialis anterior muscle of the right hindlimb.The first gene administration was on day 0, and thesecondon day 7.Samples were harvested
ondays 1, 3,5, 7,10,and 12 after the first administration ofa luciferase/HVJ-E vector (eachgroup: n=7). Luciferase activitywas measured using a luciferase
assay system. Pictures show tibia with tibialis anterior muscle (arrow) and tibia from which the periosteum was thoroughly stripped to avoid any
contamination with muscles. (B) Relative luciferase activity(RLU/mg protein) in theipsilateral tibia (withoutperiosteum),andbonemarrow ofthei p si l a t e ra l
tibia. Error bars: SEM. Each group: n=7. The dotted lines indicate the average levels of control samples, which were harvested at each time point after PBS
injection (n=6). Error bars: SEM. *p,0.05. (C) Relative luciferase activity (RLU/mg protein) in the tibia (without periosteum) on day 3 after gene transfer.
Black bar: the activity in the contralateral tibia (n=7), gray bar: the activity in the ipsilateral tibia (n=7), white bar: the activity in the tibia after injection of
PBSasacontrol(n=6).Errorbars:SEM.*p,0.05. (D)Comparison of luciferaseactivities oftheipsilateral tibia between single and repeated gene transfers on
days 10 and 12. When luciferase activity in the ipsilateral tibia without a second gene transfer is considered as 100%, its activity in the ipsilateral tibia with
second gene transfer on day 7 is shown as a percentage. Black bars: rats with the second gene transfer on day 7, white bars: rats without a second gene
transfer. Error bars: SEM. Each group: n=7. *p,0.05.
doi:10.1371/journal.pone.0013034.g001
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luciferase and CGRP were performed more than 3 times for each
specimen of nine rats.
RT-PCR
Four rats were used for RT-PCR analysis. The expression of
luciferase mRNA in the injected muscles (tibialis anterior),
ipsilateral femora, ipsilateral tibiae, and bone marrows from
ipsilateral femora and tibiae on day 3 after the first gene transfer
was examined (n=4). Periostea were entirely stripped from tibiae
and femora and different forceps were used for each sample
collection so that bone tissues would not be contaminated with
attached muscles. Total RNA was isolated using ISOGEN
(Nippon Gene, Tokyo, Japan) with ethanol precipitation. The
pcDNA/GL3 luciferase plasmid vector cut with the restriction
enzyme Xho I was used as the control. RT-PCR was performed
using an amplification reagent kit (TaqMan EZ RT-PCR kit;
Applied Biosystems, CA, USA) with a primer specific for firefly
luciferase (product length, 261 bp). Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mRNA levels were used as internal
controls. The primer was synthesized using an automated DNA
synthesizer. Sequence information and the thermocycling condi-
tions were as follows. luciferase primers: sense, 59-ACTGC-
CTGCGTGAGATTCTC-39; antisense, 59-CAGAGTGC TTT-
TGGCGAAGA-39; GAPDH primers: sense, 59-CTTCACCAC-
CATGGAGAAGGC-39; antisense, 59-GGCATGGACTGTGG-
TCATGAG-39; annealing temperature, 60uC; cycles, 40. The
PCR product was separated by electrophoresis in a 3% agarose
gel, and stained with ethidium bromide. Quantification was
performed using Image J software (National Institutes of Health,
Bethesda, USA; http://rsb.info.nih.gov/ij/).
We also performed RT-PCR using each sample and a primer
specific for myosin heavy chain (MHC) IIb (product length,
197 bp). MHC IIb is localized in fast-twitch muscle. Sequence
information and the thermocycling conditions were as follows:
sense, 59-CTGAGGAACAATCCAACGTC-39; antisense, 59-
TTGTGTGATTTCTTCTGTCACCT -39; annealing tempera-
ture, 59uC; cycles, 25. The PCR product was separated by
electrophoresis in a 3% agarose gel, and stained with ethidium
bromide.
Sciatic nerve transection experiment
Seven rats were used for the sciatic nerve transection
experiment. In the sciatic nerve transection group (n=7), the
unilateral (right) sciatic nerves were transected one day before
injecting an HVJ-envelope complex vector. HVJ-envelope-DNA
complex vector injection was performed in the right tibialis
anterior muscles, and then these muscles, the ipsilateral sciatic
nerves, dorsal root ganglia (L4 and L5), and tibiae (without bone
marrows and periostea) were harvested on day 3 after the
injection. Then, luciferase assay was performed as described
above.
Statistical analysis
Data are expressed as mean vlues 6 standard error of mean
(SEM). Dunnet’s test was used for luciferase activity between the
gene transfection group and the control group. Unpaired Student’s
t-test was used to analyze the difference between the luciferase
activities of tibia with single and repeated gene transfers, and
between the intact sciatic nerve group and the sciatic nerve
transection group. P values less than 0.05 were considered to
indicate statistical significance.
Figure 2. Immunohistochemical analysis of luciferase gene
products (green) in the bone. Nuclei (blue) were stained with DAPI.
(A) There were many immunoreactive muscle fibers in the injected
muscle. (B) The ipsilateral sciatic nerve and (C) dorsal root ganglia were
also immunoreactive. (D) Hematoxylin-eosin staining of different
sections obtained from the same CMC compoud of (E). (E) Sensory
neurons in the ipsilateral dorsal root ganglion showed luciferase protein
expression. (F) The ipsilateral tibia showed immunoreactivity as well. (G)
CGRP staining of the serial section of (H). CGRP protein was detected
(arrows) in the area where luciferase protein was expressed in (H). (H)
The luciferase protein was expressed (arrows) in a tube-like structure
known as a Haversian or Volkmann’s canal in the cortical bone.
Immunohistochemical stainings were performed more than 3 times for
each specimen and all the results were the same as shown here.
doi:10.1371/journal.pone.0013034.g002
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Gene expression in the interior of the bone by
intramuscular administration of an HVJ-envelope-DNA
complex
We utilized a combination of a luciferase reporter gene plasmid
[24] and a nonviral HVJ envelope vector [25] [hereafter referred to
as a ‘‘luciferase/HVJ-E vector’’ (see also Materials and Methods
section)] to examine the efficacy of gene induction in bones via
neuronal transport following the intramuscular injection of a vector.
The tibialis anterior muscles, sciatic nerves, dorsal root ganglia (L4
and L5), femora, tibiae, and bone marrows from bilateral femora
and tibiae were harvested on days 1, 3, 5, 7, 10, and 12 after the
administration of a luciferase/HVJ-E vector (Fig. 1A). A marked
increase in luciferase activity was observed in the injected muscle,
the ipsilateral nerve, and dorsal root ganglia (L4 and L5), as in our
previous report [23]. To our surprise, the ipsilateral tibia showed a
highincrease in luciferase activity, while the tibial bone marrow and
thecontralateraltibiashowed noincrease(Figs.1B and C).Next,we
investigated whether repeated gene transfer could lead to a
sustained luciferase gene expression in the bones. The second gene
transfer led to upregulated luciferase activity in the ipsilateral tibia
(Fig. 1D), confirming the validity of repeated gene transfer in our
method. These results showed the feasibility of inducing a sustained
gene expression in bones following injections of an HVJ-envelope-
DNA complex vector into the muscle.
Immunohistochemical analysis of luciferase gene
products in the bone
To further evaluate the detailed distribution of the introduced
gene expression, immunohistochemical staining for luciferase was
performed with an anti-luciferase antibody (more than 3 times for
each specimen of nine rats). As shown in Figs. 2A to E, luciferase
protein was detected in the injected muscle, ipsilateral sciatic nerve,
anddorsalrootganglia(L4and L5).Intheipsilateraltibia,luciferase
expression was also detected, in accordance with the observed
Figure 3. Expression of luciferase mRNA in the bone. (A) RT-PCR was performed with a primer specific for firefly luciferase (product length,
261 bp). Luciferase mRNA was detected in the rat RNA extracted from the femur as well as the tibia. (B) Using four rats, RT-PCR for luciferase mRNA
was performed 4 times. Quantification was performed using Image J software (n=4). Error bars: SEM. (C) To ensure that there was no contamination
of tibialis anterior muscle in any of the bone samples, RT-PCR was performed using all the above samples and a primer specific for MHC IIb (product
length, 197 bp). MHC IIb mRNA was not detected in the ipsilateral femora, ipsilateral tibiae, or bone marrows from ipsilateral femora and tibiae (n=4).
doi:10.1371/journal.pone.0013034.g003
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(Fig.2F).High-magnificationcross-sectionalimagesshowedthat the
luciferase protein was expressed in a tube-like structure known as a
Haversian or Volkmann’s canal in the cortical bone (Figs. 2G and
H). In the cortical bone, Haversian canals run longitudinally down
the center of the osteon, and Volkmann’s canals run perpendicu-
larly to interconnect with the Haversian canals. Both Haversian and
Volkmann’s canals contain an arteriole, a venule, a lymph duct, and
a nerve fiber [18]. From the section stained with the anti-CGRP
antibody (Fig. 2G), we assumed that nerves in the interior of the
tibia expressed luciferase protein, because CGRP is contained in
peripheral sensory nerves and distributed in bone via sensory
nerves. No immunoreactivity was detected in the control samples,
i.e., the contralateral tibialis anterior muscle, sciatic nerve, dorsal
root ganglia, and tibia (Figs. 2A–C and F).
Note that no infiltration of inflammatory mononuclear cells was
detected in the cortical bone examined at any defined time point (data
not shown), indicating a low immunogenicity of this nonviral vector.
Axonal transport mediates gene transduction in the
interior of bone
The observation that nerves express the transduced luciferase
gene lends support to the notion that axonal transport is crucial for
gene delivery into bone. If so, we assumed that luciferase gene
products would also be expressed in the ipsilateral femur and
ipsilateral tibia. Luciferase mRNA was detected in the ipsilateral
femur, albeit at a low level, by RT-PCR analysis using primers
specific for firefly luciferase (Figs. 3A and B). However, we
detected no luciferase proteins in the ipsilateral femur, possibly
owing to the low expression level and threshold for the
immunohistochemical detection (data not shown).
To ensure that there was no contamination of tibialis anterior
muscle in any of the bone samples, RT-PCR was performed using
all the above samples and a primer specific for MHC IIb, which is
specifically expressed in fast-twitch muscle. MHC IIb mRNA was
not detected in the ipsilateral femora, ipsilateral tibiae, or bone
marrows from ipsilateral femora and tibiae (n=4) (Figs. 3C).
To further clarify the role of axonal transport in gene delivery
into bone, we next examined the effect of sciatic nerve transection.
Sciatic nerves were cut prior to the injection of a vector and
samples were harvested on day 3 after the administration (Fig. 4A).
We found that sciatic nerve transection makes the gene expression
ineffectual in the tibia as well as in the sciatic nerve and dorsal root
ganglia (L4 and L5), while the gene expression in the tibialis
anterior muscle was not affected (Fig. 4B). It is tempting to
speculate that the luciferase gene (or its gene products) may be
conveyed into bones mainly via axonal transport, although we
could not exclude the minor contribution via the blood or the
lymphatics. Furthermore, we should take the lack of muscle
contraction into account, because tibialis anterior muscles were
not able to contract actively after sciatic nerve transection.
Discussion
Local gene delivery into bone is problematic owing to the
limited accessibility of the interior of bone, and its trials have
remained preclinical for a long time [1,13]. In this study, we
demonstrated that efficient gene expression within bone is simply
achieved by an intramuscular vector injection with a minimal
immune response allowing repeated administrations. Although the
detailed mechanism of this gene transduction remains uncertain,
we suggest that gene expression within bones may be predomi-
nantly mediated by axonal transport.
Many studies have reported evidence for the existence of
dichotomizing axons of primary sensory neurons [26,27], although
there has been no report detailing how many sensory neurons
project to both tibia and tibialis anterior muscle. If dorsal root
ganglion neurons with dichotomizing axons innervating both bone
and muscle exist, we could speculate two mechanisms of gene
transduction in the interior of bone (Fig. 5). Large numbers of
sensory nerves innervate not only fasciae but also muscle spindles
[28,29], and it has been reported that nonviral vectors may assist
the retrograde axonal gene transfer and the reporter gene product
may also be synthesized in DRG [30,31]. On the basis of the
above reports and our results that the levels of luciferase activity
peaked on day 3 after gene transfection, we speculate first that the
vector may be transported to DRG and back to peripheral sites by
fast axonal transport. However, the ipsilateral tibia showed a high
luciferase activity on day 1(Fig. 1B). Therefore, it is unlikely that
the vector is transported to DRG and back to peripheral sites in
only 1 day, even if conveyed by fast axonal transport, because fast
retrograde axonal transport has been observed at rates of 100–
410 mm in 1 day [32–34]. Next, we consider it possible that the
plasmid vector or its gene product is transported to sciatic nerves
via retrograde axonal flow from the tibialis anterior muscle,
conveyed to the other branch of the axon at its division point, and
Figure 4. Sciatic nerve transection experiment. (A) Experimental
design of sciatic nerve transection. The unilateral (right) sciatic nerves
were transected 1 day before injecting an HVJ-envelope complex
vector. HVJ-envelope-DNA complex vector injection was performed in
the injected tibialis anterior muscle. Samples were harvested 3 days
after the administration of a luciferase/HVJ-E vector. (B) Comparison of
luciferase activities between the intact sciatic nerve group samples
(white bars) and the sciatic nerve transection group samples (black
bars) on day 3 after gene transduction (n=7). Error bars: SEM. *p,0.05.
doi:10.1371/journal.pone.0013034.g004
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detailed characterization of such pathways is required for better
understanding of axonal-transport-mediated gene transduction.
Meanwhile, when we introduce an exogenous gene into peripheral
nerves to treat nerve disorders, we should consider that gene
expression might also occur within bone via axonal transport.
In conclusion, we have demonstrated that the injection of an
HVJ-envelope-DNA complex into an innervated muscle can
achieve efficient gene expression in the interior of bone, and that
sustained gene expression can be obtained by repeated gene
transfers. Although we carried out only a short-term analysis, our
findings may provide new insights into the development of a
possible therapeutic alternative for hard-tissue disorders.
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